CurrentBlue Cross Blue Shield - MassachusettsPolicy 480

Semi‑ and Fully Implantable Middle Ear Hearing Aids (Active Middle Ear Implants)

Blue Cross Blue Shield Massachusetts clinical policy addressing coverage considerations, prior authorization requirements, coding, and evidence summary for semi‑implantable and fully implantable middle ear hearing aids (e.g., Vibrant Soundbridge, Maxum, Esteem) for Commercial and Medicare products.

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicySemi‑ and Fully Implantable Middle Ear Hearing Aids (Active Middle Ear Implants)

Policy CodePolicy 480

Change TypeCoding clarificationannual review

Effective Date

Next Review Date

Key ActionObtain precertification/preauthorization prior to any inpatient implantation procedure and report services using current procedure, revenue, and diagnosis codes with appropriate modifiers.

SourceLink

POLICY UPDATE CHANGES

5/2024: Clarified coding table.

4/2025: Annual policy review. References updated; policy statements unchanged.

1HCPCS codes listed as investigational

Commercial + MedicareProducts explicitly covered by policy header

MultipleAnnual reviews documented (2010–2025)

Policy Conclusions and Coverage Notes

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

General coverage conclusion

Policy conclusion based on the evidence summary:

Evidence-based conclusion

For sensorineural hearing loss, semi- and fully implantable devices may provide some improvement compared with external acoustic hearing aids, but the evidence is limited and insufficient to determine improvement in net health outcome.
For conductive or mixed hearing loss and aural atresia when external acoustic hearing aids are not an option, some studies demonstrate benefit but are limited; conclusions on safety and effectiveness are limited.

Prior authorization requirements

When procedure is inpatient:

ALL of the following

Precertification/preauthorization IS REQUIRED for all products if the procedure is performed inpatient.

Outpatient prior authorization / coverage note

Outpatient coverage and authorization status varies by product:

ALL of the following

For outpatient services described in this policy, the policy indicates 'This is not a covered service' across Commercial PPO and Indemnity, Medicare HMO BlueSM, and Medicare PPO BlueSM (i.e., outpatient placement considered not covered for those products).

Authorization, Documentation, and Billing Rules

Prior Authorization

Preauthorization required for inpatient procedures

Precertification/preauthorization is required for all products when the implant procedure is performed inpatient; providers must obtain authorization prior to inpatient admission.

S2230
V5095

Documentation Required

Report up-to-date codes and modifiers

Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.

Clinical and Evidence Summary

Semi‑ and fully implantable middle ear hearing aids are surgical alternatives to conventional external acoustic hearing aids that mechanically or electrically transduce sound directly to the ossicular chain. Semi‑implantable devices (examples: Vibrant Soundbridge, Maxum) include an implanted magnet or floating mass transducer attached to the ossicles, a receiver under the skin, and an external sound processor that transmits amplified signals to the implanted component via electromagnetic coupling. Fully implantable devices (example: Esteem) contain an implanted sensor, processor, and driver that use piezoelectric transduction to convert tympanic membrane vibrations into electrical signals and drive the ossicles without an external processor. (See device descriptions and mechanisms.)

The published evidence consists primarily of FDA premarket single‑arm interventional studies, observational case series, and systematic reviews. These reports indicate that implantable middle ear devices can provide some improvement in hearing compared with conventional external hearing aids for selected patients with sensorineural hearing loss, and that semi‑implantable devices have shown benefit in some patients with conductive or mixed hearing loss or aural atresia when external aids are not feasible. However, the clinical evidence is limited by small sample sizes, largely nonrandomized designs, and a median duration of follow‑up typically 5 years in many trials, which constrains conclusions about long‑term safety and net health benefit.

Because external acoustic hearing aids are effective and carry substantially lower procedural risk, implantable middle ear devices should demonstrate clinically significant improvement in hearing parameters compared with external devices to justify surgical implantation. Available studies suggest minimal safety concerns in the short term, but the limited numbers of patients, short follow‑up, and sparse comparative data (including comparisons with bone‑conduction or bone‑anchored devices) mean the evidence is currently insufficient to definitively determine improvement in net health outcomes for many indications. Annual policy review and coding clarifications have been documented, with policy statements unchanged in recent updates.

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicySemi‑ and Fully Implantable Middle Ear Hearing Aids (Active Middle Ear Implants)

Policy CodePolicy 480

Change TypeCoding clarificationannual review

Effective Date

Next Review Date

Key ActionObtain precertification/preauthorization prior to any inpatient implantation procedure and report services using current procedure, revenue, and diagnosis codes with appropriate modifiers.

SourceLink

On This Page

OpenPayer

Semi‑ and Fully Implantable Middle Ear Hearing Aids (Active Middle Ear Implants)

Policy Conclusions and Coverage Notes

Codes and Coding Guidance

Authorization, Documentation, and Billing Rules

Clinical and Evidence Summary

Key Definitions

Policy Update Changes

S2230	Implantation of magnetic component of semi-implantable hearing device on ossicles in middle ear
V5095	Semi-implantable middle ear hearing prosthesis

Semi‑ and Fully Implantable Middle Ear Hearing Aids (Active Middle Ear Implants)

Policy Conclusions and Coverage Notes

Codes and Coding Guidance

Authorization, Documentation, and Billing Rules

Clinical and Evidence Summary

Key Definitions

Also see

Policy Update Changes